Andrew Allen, Gritstone bio CEO (Gritstone via website)
July 22, 2022 11:08 AM EDTUpdated 04:01 PM
Financing

Up­dat­ed: Grit­stone goes the cred­it fa­cil­i­ty route, se­cur­ing $80M to keep clin­i­cal ef­forts run­ning

Paul Schloesser

Associate Editor

A Cal­i­for­nia de­vel­op­er is fol­low­ing up on one of the hottest trends in biotech, tak­ing out a loan to ex­tend its op­er­at­ing run­way while the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times